Jacob Sonenshine is a Reporter at Barron's. He covers a range of topics within finance and trading, including financial markets, personal finance, commodities, and technology, while also exploring themes related to business leaders and U.S. politics. Jacob's work has been featured in notable publications such as Barron's, Financial News, and MarketWatch.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jacob Sonenshine's coverage primarily focuses on investment analysis, with an emphasis on the stock market and specific sectors such as bank stocks. He frequently cites data in his articles, indicating a preference for fact-based insights.
Given his focus, Jacob would likely be interested in receiving input from financial analysts or experts who can provide detailed and data-driven perspectives on the stock market trends, particularly within small-cap stocks, S&P 500 movements, and bank stocks' performance.
While he doesn't have a specified geographic focus, Jacob predominantly covers the United States’ financial landscape. Therefore, pitches should align with developments relevant to this region unless they have broader global implications.
This information evolves through artificial intelligence and human feedback. Improve this profile .
If the still-rapid growth of artificial intelligence isn’t pushing the market higher right now, something else will have to do it.
By: Jacob Sonenshine
The latest data from Morgan Stanley show the last 12 months has seen about $4 trillion in deal value, and the trend should continue next year.
The reality is that the likes of Microsoft and Google parent Alphabet aren’t going to stop pouring billions into chatbots. Ultimately, owning the usual suspects—Big Tech stocks—is the right move. This is on top of the fact that some are concerned about the billions poured into generative AI by Microsoft and Alphabet as well as Amazon Facebook parent, Meta Platforms, and other big names.
By: Jacob Sonenshine
President-elect Donald Trump is proposing allowing companies to record their domestic research and development expense immediately instead of amortizing them over five years.
By: Jacob Sonenshine
For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just over $117 billion, fell from roughly $89 in the middle of 2016 through June. Earnings per share shrank as the company struggled to find opportunities beyond sales of Biktarvy, the HIV drug that accounts for nearly half of annual sales.
If the economy continues growing, but only moderately, it could lift a certain group of potentially volatile stocks including Southwest Airlines and lithium miner Albemarle.
The streaming service is riding to a split on what the likes of Nvidia and Chipotle did—the broad market rally.
By: Jacob Sonenshine
In This Article CAT ^GSPC Stubborn inflation means the central bank may not be able to cut rates as many times as the market expected.
By: Jacob Sonenshine
Key technical levels are starting to break. The stock has dropped below short-term moving averages, a sign that gravity is starting to kick in.
By: Jacob Sonenshine
Existing-home sales have shown signs of improvement, and it’s those sales that lead to remodeling jobs.
(833) 317-6278 
